Serum Level of Bioactive Mediators and Urinary Biopyrins in Psoriasis

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03889938

Enrollment

Registered

2019-03-26

Start date

2019-04-01

Completion date

2020-05-31

Last updated

2019-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Brief summary

1. Assess the level of lipid mediators in patients with psoriasis 2. Assess the urinary level of biopyrins as New marker of oxidative stress in patients with psoriasis 3. Correlate the serum level of bioactive lipid mediators and urinary level of biopyrins with Psoriasis Area and Severity Index

Detailed description

Psoriasis is acommon immune mediated inflammatory skin disorder of complex pathomechanisms which is generically conditioned and influenced by environmental factors

Interventions

DIAGNOSTIC_TESTSerum and urinary assessment

Assess bioactive lipid mediators in blood and biopyrins in urine

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

12 Years to 80 Years

Inclusion criteria

* age from12 to 80 and both sex

Exclusion criteria

* patients with other dermatological disorders

Design outcomes

Primary

Measure	Time frame	Description
the serum level of bioactive lipid mediators in patients with psoriasis	1 month	Bioactive lipid mediators (LMs) are potent compounds reported to play a role in the development and resolution of inflammation.

Contacts

Primary ContactShimaa Mahrous

shimaamahrous9@gmail.com01011845338

Backup ContactEman Kamal, Ass prof

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026